{"id":"NCT01405560","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)","officialTitle":"A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Were Non-responders to Previous Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-02","primaryCompletion":"2013-03-29","completion":"2013-03-29","firstPosted":"2011-07-29","resultsPosted":"2014-10-09","lastUpdate":"2018-10-18"},"enrollment":42,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Vaniprevir","otherNames":["MK-7009"]},{"type":"BIOLOGICAL","name":"peg-IFN","otherNames":["PegIntron"]},{"type":"DRUG","name":"ribavirin","otherNames":["REBETOL®"]}],"arms":[{"label":"Vaniprevir 24 Week Arm","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir (300 mg twice daily) given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) in Japanese participants with chronic hepatitis C (CHC) genotype (GT) 1 who have not responded to previous treatment. The primary efficacy objective is to estimate efficacy of vaniprevir, peg-IFN and RBV for 24 weeks as assessed by the percentage of participants achieving undetectable Hepatitis C Virus ribonucleic acid (HCV RNA) 24 weeks after completion of all study therapy (Sustained Viral Response 24 \\[SVR24\\]).","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response (SVR)24","timeFrame":"24 weeks after 24 weeks of study therapy (up to 48 weeks)","effectByArm":[{"arm":"Vaniprevir 24 Week Arm","deltaMin":61.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26936417","26947564"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":42},"commonTop":["Pyrexia","Nausea","Platelet count decreased","Pruritus","Neutrophil count decreased"]}}